Evidence map›Paper›PMID 41994332›Full record

ArticleiScience2026

Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer.

Florian Laforêts, Panoraia Kotantaki, Samar Elorbany, Joseph Hartlebury, Joash D Joy, Beatrice Malacrida, Rachel C Bryan-Ravenscroft, Chiara Berlato, Erica Di Federico, John F Marshall and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Florian LaforêtsBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Panoraia KotantakiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Samar ElorbanyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Joseph HartleburyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Joash D JoyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Beatrice MalacridaBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Rachel C Bryan-RavenscroftBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Chiara BerlatoBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Erica Di FedericoSchool of Engineering and Materials Science, Faculty of Science and Engineering, Queen Mary University of London, Mile End Road, London E1 4NS, UK.
John F MarshallBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Ranjit ManchandaWolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Wolfgang JarolimekSyntara Limited, Unit 2, 20A Rodborough Road, Locked Bag 5015, Frenchs Forest, NSW 2086, Australia.
Lara PerrymanSyntara Limited, Unit 2, 20A Rodborough Road, Locked Bag 5015, Frenchs Forest, NSW 2086, Australia.
Eleni ManiatiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.
Frances R BalkwillBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London ECM1 6BQ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated extracellular matrix (ECM) associates with chemo-resistance and poor prognosis in cancer. Modifying the ECM could enhance response to chemotherapy. We measured chemotherapy-induced changes in the tumor microenvironment (TME) of two high-grade serous ovarian cancer (HGSOC) mouse models with different chemo-sensitivity. Carboplatin/paclitaxel treatment triggered dynamic transcriptional changes in immune and ECM-related pathways, and analyses of the ECM structure revealed modifications in the chemo-sensitive tumors. These changes, observed over twenty days post-chemotherapy, had relevance to HGSOC patient responses. Integrating transcriptomics with ECM structure metrics, we identified ECM targets, including lysyl oxidase (LOX), that might enhance effects of chemotherapy. Given alone or with chemotherapy, a pan-LOX inhibitor, PXS-5505, modulated fibroblast and immune cell distribution and decreased tumor stiffness in the less-responsive mouse model. Moreover, treatment with PXS-5505 before chemotherapy enhanced the therapeutic response. We conclude that pretreatment with ECM targeting agents may improve chemotherapy efficacy by altering ECM structure and immune responses.

Indexed as

biological sciencescancermicroenvironmentsequence analysis

Identifiers

PMID41994332
PMCPMC13080397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.